Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

May 19, 2026

Study Completion Date

November 19, 2026

Conditions

Gynecological Cancers

Interventions

DRUG

PORPHYSOMES

Pegylated porphyrin-lipid conjugate-containing nanoparticle suspension

DRUG

64Cu-PORPHYSOMES

Pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension

Trial Locations (1)

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER